Strategic Partnerships Capitalize on recent collaborations with Daisy Genomics, the University of Tennessee, ETHIA, and SehaMed Global to position New Day Diagnostics as a regional hub for cancer diagnostics and early screening tools, opening doors for co-developed tests and cross-sell opportunities.

ColoHealth Growth Leverage the national rollout and distribution agreement for ColoHealth to target health systems, clinics, and insurers in the Middle East and other regions, selling scalable blood-based colorectal cancer screening and expanding adoption through partner networks.

Clinical Validation Highlight ongoing collaborations and clinical studies with international partners to strengthen evidence for epigenetic sequencing and liquid biopsy products, accelerating conversations with payers and public health programs seeking validated screening options.

Diverse Test Portfolio Promote a diversified pipeline including ColoHealth, celiac, respiratory panels, H pylori, and HCC tests from Hepion licensing, targeting hospitals and reference labs seeking a broad diagnostic suite to reduce vendor fragmentation.

Smaller Enterprise Advantage Position New Day Diagnostics as a nimble, innovator-led partner capable of rapid deployment, custom deployments, and region-specific scaling, appealing to mid-market health systems and emerging markets looking for cutting-edge diagnostics with adaptable commercialization.